« Return to News | Awards & Advancement

Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

Kelson will be managing the company's financial portfolio and business affairs. He brings more than 12 years of experience to the role of CFO. Prior to this position, Kelson served as executive vice president and CFO for Insight Health Services Holdings, a diagnostic imaging firm with more than 1,300 employees and $180 million in revenue. Prior to that, Kelson served as CFO at SecurusTechnologies, a $400 million telecommunications and software company.

Doren will be responsible for overseeing the biostatistics, data management and IT services departments, in order to provide executive oversight and continuity. Doren's 20 years of clinical development experience led to the creation of this new executive position. His experience has been garnered at clinical research organizations, including his most recent position as vice president, clinical data, analysis and reporting organization (CDARO) at Covance. He has also held executive positions with Quintiles, eRT, TKL Research and Kendle.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.